NOV 15, 2018 11:01 AM PST

A Subclass of Anti-Aging Compounds Serves as Alzheimer's Drug Candidates

WRITTEN BY: Nouran Amin

In a publication in Trends in Pharmacological Sciences, a subclass of anti-aging compounds, called geroneuroprotectors (GNPs), have been identified in research to hold a potential role in slowing the aging process in mice. Since aging is the greatest risk factor for Alzheimer's disease (AD)—GNPs mays serve as a potential drug candidate.

Credit: rdmag.com

Alzheimer’s disease is a progressive neurodegenerative disease that first deteriorates memory and thinking skills and, eventually, the ability to perform simple tasks. Although losing memory is common as people grow old, it is not considered a normal part of aging.

Watch a video about how Alzheimer's changes the brain:

"The argument for geroprotectors is that if one can extend the lifespan of model organisms, such as mice, and translate this effect to humans, then you should be able to slow down the appearance of many diseases that are associated with aging, such as Alzheimer's, Parkinson's, cancer and overall frailty," states Dave Schubert, first author, Salk Institute professor and head of Salk's Cellular Neurobiology Laboratory.

In the study researchers first focused on two medicinal properties found in plants fisetin, derived from fruits and vegetables, and curcumin, from the curry spice turmeric. Researchers used these compounds, to synthesize three AD drug candidates based on their ability to protect neurons from age-related toxicities in the brain. The compounds that were then synthesized are CMS121, CAD31, and J147.

"Since we found that the natural products curcumin and fisetin are also GNPs and commercially available as supplements, they could provide some therapeutic benefits right now," says Maher.

Credit: Clarke.edu

The lab has successfully shown that these synthetic compounds were able to reduce the molecular markers of aging. The researchers were able to examine that the molecular pathways associated with the AD drug candidates are the same as well-studied synthetic compounds previously shown to extend the lifespan of many animals.

Researchers are hoping to get two GNPs, CMS121 and J147, into clinical trials once FDA has approved. The study is believed to validate the drug discovery model in the promotion of healthy aging

"If these drugs have benefits for other body systems, such as maintaining kidney function and overall muscle health, they could be used in additional ways to treat or prevent the diseases of aging," Schubert says.

Source: Trends in Pharmacological Sciences, Salk Research Institute

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 11, 2022
Drug Discovery & Development
Gene Therapy Shows Promise for Neuropathic Pain
MAY 11, 2022
Gene Therapy Shows Promise for Neuropathic Pain
A gene therapy has been able to inhibit neuropathic pain with no detectable side effects in mice with spinal cord and pe ...
JUN 02, 2022
Cancer
Call to Diversify Clinical Trials
JUN 02, 2022
Call to Diversify Clinical Trials
Clinical Trials represent an integral component of biomedical research.  These research studies utilize human subje ...
JUN 04, 2022
Drug Discovery & Development
Antibiotics Reduce Motivation to Exercise in Mice
JUN 04, 2022
Antibiotics Reduce Motivation to Exercise in Mice
Antibiotics may decrease athletes' motivation and endurance via effects on the microbiome. The corresponding study w ...
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
JUN 24, 2022
Cannabis Sciences
Decrease in Youth Substance Use During the Pandemic
JUN 24, 2022
Decrease in Youth Substance Use During the Pandemic
A review published in Child and Family Disaster Psychiatry found that youth substance use declined during the COVID-19 p ...
JUN 27, 2022
Cancer
A Genomic Scan Detects Cancer-Driving Mutations
JUN 27, 2022
A Genomic Scan Detects Cancer-Driving Mutations
Cancer develops when the DNA in our cells becomes altered, resulting in a gene mutation.  DNA alterations can occur ...
Loading Comments...